Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics

Molecular Therapy - United States
doi 10.1016/j.ymthe.2018.10.016
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Monoclonal and Bispecific Antibodies as Novel Therapeutics

Archivum Immunologiae et Therapiae Experimentalis
MedicineAllergyImmunology
2006English

Lipid Lowering Therapy and Circulating PCSK9 Concentration

Journal of Atherosclerosis and Thrombosis
BiochemistryInternal MedicineCardiovascular MedicineCardiology
2017English

PCSK9 Monoclonal Antibodies for the Primary and Secondary Prevention of Cardiovascular Disease

2015English

In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect Against Ebolavirus Infection in a Mouse Model

Cell Reports
BiochemistryGeneticsMolecular Biology
2018English

Targeting DNA Replication and Repair for the Development of Novel Therapeutics Against Tuberculosis

Frontiers in Molecular Biosciences
BiochemistryGeneticsMolecular Biology
2017English

Evaluation of Wheat Content With Monoclonal Antibodies Against Lipid Transfer Protein

Nippon Shokuhin Kagaku Kogaku Kaishi
Food Science
2009English

Key Recent Advances in Atherosclerosis Treatment With Modern Lipid-Lowering Drugs: The New Frontier With PCSK9 Inhibitors

European Cardiology Review
Cardiovascular MedicineCardiology
2017English

Novel Mouse Monoclonal Antibodies Specifically Recognize Aspergillus Fumigatus Galactomannan

PLoS ONE
Multidisciplinary
2018English

Monoclonal Antibodies

Science
MultidisciplinaryPhilosophy of ScienceHistory
1996English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy